INDBInternet News Database 2.5 Updated 2 min ago · 293 sources Show or hide images Light or dark

Results for “Novo Nordisk's Ozempic”

Health
26 sources

Who is covering this

Associated PressCenterPBS NewsHourLeans leftBBC NewsCenterThe GuardianLeftCBS NewsLeans leftNBC NewsLeans leftABC News (US)Leans leftSky NewsLeans rightCNBCCenterThe HinduLeans leftUSA TODAYLeans leftThe HillCenterGoogle NewsCenterNDTVCenterQuartzLeans leftGizmodoLeans leftMedpagetodayCenterTimes of IndiaCenterMedscapeCenterNew York PostRightZero HedgeRightWSNS-TVNot ratedThe Seattle TimesNot ratedKING-TVNot ratedKHOUNot ratedAll 26 outlets
Truth score 918
Left 43%43%Centre 43%43%Right 14%14%
BBC NewsCenter

Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness

The Food and Drug Administration is adding a new warning about possible rare cases of vision loss reported with GLP-1 drugs like Ozempic, Wegovy and other brands. The Food and Drug Administration is adding a new warning about possible...

Lean: Center Fact-focusedFactuality: Very highCountry: United KingdomFunding: Public broadcasterOwner: BBC (UK Government)
  • The Guardian FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications

    The federal agency is requiring all GLP-1s to include information about the potential risk on warning labels The US Food and Drug Administration (FDA) has issued a new warning on GLP-1 medications – which can...

    Lean: Left Fact-focusedFactuality: Very highCountry: United KingdomFunding: Nonprofit trustOwner: Scott Trust
  • ABC News (US) FDA adds new warning on GLP-1 drugs for rare eye condition

    The U.S. Food and Drug Administration announced Monday that it is requiring new warnings on popular diabetes and weight loss drugs, including Ozempic, Wegovy, Mounjaro and Zepbound, over a potential increased risk...

    Lean: Leans left VideoFactuality: HighCountry: United StatesFunding: CorporateOwner: Walt Disney Company
  • Associated Press FDA adds rare vision-loss warning to popular GLP-1 drugs

    Popular weight loss drugs, including Ozempic and Wegovy, will carry a new warning about the possibility of a rare side effect that can lead to permanent vision loss, U.S. health regulators announced Monday.

    Lean: Center VideoFactuality: Very highCountry: United StatesFunding: NonprofitOwner: AP (Cooperative)
  • PBS NewsHour FDA issues vision loss warning for GLP-1 drugs

    The Food and Drug Administration issued a new warning on Monday about the risk of vision loss related to popular GLP-1 weight loss and diabetes drugs. Health officials say drugs like Eli Lilly’s Zepbound and Ozempic...

    Lean: Leans left VideoFactuality: Very highCountry: United StatesFunding: Public broadcasterOwner: PBS (Nonprofit)
+ 31 · Full coverage
Coverage breakdown
Funding
Corporate58%
Not recorded19%
Public broadcaster8%
Private8%
Nonprofit4%
Countries
United States77%
India12%
United Kingdom12%
Media ownership
Independent19%
Comcast12%
G/O Media12%
WSNS-TV6%
Google News6%
Avg reliability75
Low-credibility share5%
Fact / opinion36/0
State media0%
More analysis
Truth score: 91 (Strongly corroborated) Propaganda risk: 0 Trending: Low Sources: 26 Reliability: 75 Bias severity: 50 Risk: 5Sentiment: -94Sensationalism: 0 Amplification: 0

How we score

Analyze: Misinfo Radar
Like
Health
2 sources

Who is covering this

ReutersCenterYahoo NewsCenter
Truth score 531
Centre 100%100%
ReutersCenter

Novo Nordisk's Wegovy pill beats forecasts as it battles Lilly

Novo Nordisk's Wegovy pill beats forecasts as it battles Lilly Reuters

Lean: Center Fact-focusedFactuality: Very highCountry: United KingdomFunding: CorporateOwner: Thomson Reuters
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United Kingdom50%
United States50%
Media ownership
Thomson Reuters50%
Apollo Global Management50%
Avg reliability81
Low-credibility share0%
Fact / opinion2/0
State media0%
More analysis
Truth score: 53 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 2 Reliability: 81 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Analyze: Coverage Heat Map
Like
Business
3 sources

Who is covering this

CNBCCenterGoogle NewsCenterLivemintCenter
Truth score 58
Centre 100%100%
CNBCCenter

CVS Health plans to split itself up. Here's why a breakup could make sense now

Analysts say that after a roughly two-year turnaround the company's retail pharmacy business and other units may be strong enough to stand on their own. Covered by 3 outlets: 3 are centre.

Lean: Center Fact-focusedFactuality: HighCountry: United StatesFunding: Corporate
+ 1 · Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United States67%
India33%
Media ownership
Independent33%
CNBC33%
Google News33%
Avg reliability78
Low-credibility share0%
Fact / opinion4/0
State media0%
More analysis
Truth score: 58 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 3 Reliability: 78 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 8 Amplification: 0

How we score

Analyze: Compare coverage
Like
Crime and Justice
1 source

Who is covering this

ReutersCenter
Truth score 47
Centre 100%100%
ReutersCenter

Trial failures of Novartis, Novo Nordisk heart drugs leave experts guessing

Trial failures of Novartis, Novo Nordisk heart drugs leave experts guessing Reuters

Lean: Center Fact-focusedFactuality: Very highCountry: United KingdomFunding: CorporateOwner: Thomson Reuters
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United Kingdom100%
Media ownership
Thomson Reuters100%
Avg reliability92
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 47 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 92 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Analyze: Coverage Heat Map
Like
World
1 source

Who is covering this

The Epoch TimesRight
Truth score 17Factuality: Low
Right 100%100%
The Epoch TimesRight

First Weight-Loss Tablet Approved for Use in Australia

Low reliability sourceElevated risk

A sign bearing the logo of Novo Nordisk next to the company's factory in Hillerod, Denmark, on Nov. 12, 2025. (Sergei Gapon/AFP via Getty Images)

Lean: Right Fact-focusedFactuality: LowCountry: United StatesFunding: PrivateOwner: Epoch Media Group
Full coverage
Coverage breakdown
Funding
Private100%
Countries
United States100%
Media ownership
Epoch Media Group100%
Avg reliability35
Low-credibility share100%
Fact / opinion1/0
State media0%
More analysis
Truth score: 17 (Weakly supported) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 35 Bias severity: 0 Risk: 100Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Analyze: Coverage Heat Map
Like
1 source

Who is covering this

CNBCCenter
Truth score 43
Centre 100%100%
CNBCCenter

Novo raises full-year outlook as Wegovy pill sales impress

Novo posted quarterly earnings ahead of expectations early Wednesday as sales of its Wegovy pill blew past estimates

Lean: Center Fact-focusedFactuality: HighCountry: United StatesFunding: Corporate
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United States100%
Media ownership
CNBC100%
Avg reliability80
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 43 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 80 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Analyze: Story Timeline
Like
Entertainment
1 source

Who is covering this

DeadlineCenter
Truth score 41
Centre 100%100%
DeadlineCenter

Narrative Global Sales Takes Three Genre Films To AFM Including Jenna Kanell Sci-Fi ‘De Novo’ With Lilly Wachowski Aboard

EXCLUSIVE: Lilly Wachowski’s Anarchists United with Sarah Marie Flores and Lawrence Mattis have joined the upcoming sci-fi film De Novo as executive producers. Written and directed by Terrifier actress Jenna Kanell, and currently in...

Lean: Center Fact-focusedFactuality: HighCountry: United StatesFunding: CorporateOwner: Penske Media Corporation
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United States100%
Media ownership
Penske Media Corporation100%
Avg reliability75
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 41 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 75 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Analyze: Coverage Heat Map
Like
Health
1 source

Who is covering this

MedscapeCenter
Truth score 38
Centre 100%100%
MedscapeCenter

DCBs Hold Their Own Against Stents in De Novo Lesions

In noncomplex coronary artery disease, a drug coated-balloon is noninferior to a drug-eluting stent at 12 months.

Lean: Center Fact-focusedFactuality: Mostly factualCountry: United StatesFunding: CorporateOwner: Independent
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United States100%
Media ownership
Independent100%
Avg reliability65
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 38 (Weakly supported) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 65 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Analyze: Coverage Heat Map
Like
Health
1 source

Who is covering this

MedpagetodayCenter
Truth score 38
Centre 100%100%
MedpagetodayCenter

Study Strengthens Case for Stent-Free PCI in De Novo Coronary Lesions

(MedPage Today) -- For de novo coronary lesions, drug-coated balloons (DCBs) were just as effective as standard drug-eluting stents, the TRANSFORM II trial showed. Among patients with native coronary lesions undergoing percutaneous...

Lean: Center Fact-focusedFactuality: Mostly factualCountry: United StatesFunding: CorporateOwner: Independent
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United States100%
Media ownership
Independent100%
Avg reliability65
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 38 (Weakly supported) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 65 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Analyze: Misinfo Radar
Like